Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine

[1]  M. Thase,et al.  Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs , 2008, Biological Psychiatry.

[2]  C. Nemeroff.  The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.

[3]  G. Debonnel,et al.  Differential physiological effects of a low dose and high doses of venlafaxine in major depression. , 2007, The international journal of neuropsychopharmacology.

[4]  Jack M. Gorman,et al.  A Guide to Treatments That Work , 2007 .

[5]  J. Davidson,et al.  Effects of Paroxetine and Venlafaxine XR on Heart Rate Variability in Depression , 2005, Journal of clinical psychopharmacology.

[6]  K. Krishnan,et al.  Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy , 2005, Neuropsychopharmacology.

[7]  Sylvain Houle,et al.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.

[8]  M. Owens.  Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. , 2004, The Journal of clinical psychiatry.

[9]  C. Mazure,et al.  Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study , 2003, Biological Psychiatry.

[10]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[11]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[12]  Michael J. Owens,et al.  Treatment of mood disorders , 2002, Nature Neuroscience.

[13]  C. Nemeroff,et al.  Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. , 2002, The American journal of psychiatry.

[14]  Alan A. Wilson,et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.

[15]  A Frazer,et al.  Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. , 2001, The Journal of clinical psychiatry.

[16]  M. Thase,et al.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors , 2001, British Journal of Psychiatry.

[17]  R. Rubin.  Paroxetine binding to the rat norepinephrine transporter in vivo , 2000, Biological Psychiatry.

[18]  A. Gjedde,et al.  Basic CNS Drug Transport and Binding Kinetics In Vivo , 2000 .

[19]  S. Preskorn,et al.  Evidence of the dual mechanisms of action of venlafaxine. , 2000, Archives of general psychiatry.

[20]  D. Palao,et al.  The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia , 2000, International clinical psychopharmacology.

[21]  J. Gregson.  Venlafaxine and paroxetine in treatment-resistant depression , 1999, British Journal of Psychiatry.

[22]  K. Audus,et al.  Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium , 1999, Brain Research.

[23]  E. Smeraldi,et al.  Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. , 1998, The Journal of clinical psychiatry.

[24]  G. Debonnel,et al.  Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. , 1998, European journal of pharmacology.

[25]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[26]  C. Nemeroff,et al.  Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  D. Zabel,et al.  Diagnostic and Statistical Manual of Mental Disorders, 4th ed , 1995 .

[28]  G. Bricca.  Pharmacological analysis of drug-receptor interaction, T Kenakin. Raven Press, New York (1993), 1 vol, 443 p. , 1994 .

[29]  C. Alling,et al.  The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients , 1994, European Neuropsychopharmacology.

[30]  M. Kietzmann.  Pharmacological analysis of drug-receptor interaction: Kenakin, T., 2nd Edn, XII + 483 pp. New York: Raven Press (1993) , 1994 .

[31]  K. Bergmann,et al.  Combination Treatment with Noradrenalin and Serotonin Reuptake Inhibitors in Resistant Depression , 1992, British Journal of Psychiatry.

[32]  C. Mazure,et al.  A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. , 1991, Archives of general psychiatry.

[33]  P. Tyrer,et al.  Clinical efficacy of paroxetine in resistant depression , 1987, Journal of psychopharmacology.

[34]  M. Scheinin,et al.  Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. , 1985, Archives of general psychiatry.

[35]  E. Robins,et al.  Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Relationship to plasma levels and treatment outcome. , 1985, Journal of affective disorders.

[36]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[37]  F. Goodwin,et al.  Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. , 1978, Archives of general psychiatry.

[38]  R. Ohman,et al.  Studies on serum protein binding of haloperidol. , 1977, Current therapeutic research, clinical and experimental.

[39]  C. Nemeroff,et al.  Pharmacological treatments for unipolar depression. , 2007 .

[40]  P. Linkowski,et al.  Haloperidol plasma levels and clinical response in paranoid schizophrenics , 2004, European archives of psychiatry and neurological sciences.

[41]  C. Nemeroff,et al.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. , 2001, Biological psychiatry.

[42]  J. Nelson,et al.  Synergistic benefits of serotonin and noradrenaline reuptake inhibition , 1998, Depression and anxiety.

[43]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[44]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[45]  Nelson Jc.  Synergistic benefits of serotonin and noradrenaline reuptake inhibition. , 1998 .

[46]  J. Levenson,et al.  Fluoxetine treatment of depression caused by interferon-alpha. , 1993, The American journal of gastroenterology.